Structure Therapeutics Q4 net loss $24.5M; cash $467.3M; Phase 2a data due Q2 2024

Structure Therapeutics Inc.

Net loss for Q4 2023 was $24.5M ($89.6M full year); compared to $11.9M in Q4 2022.
Cash and equivalents $467.3M at year-end; expected to fund operations through 2026.
Topline GSBR-1290 Phase 2a obesity data (12-week) expected latter half of Q2 2024.
Phase 2b obesity study of GSBR-1290 planned to start Q4 2024.
R&D expenses $20.0M in Q4 2023 ($70.1M full year), up from $8.4M in Q4 2022.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Structure Therapeutics Inc. reported the fourth quarter of 2023 results: net income Net loss for the fourth quarter of 2023 totaled $24.5.

Period: the fourth quarter of 2023
Net income: Net loss for the fourth quarter of 2023 totaled $24.5
Result: reported results

Exact text from the filing

Net loss for the fourth quarter of 2023 totaled $24.5, with non-cash stock-based compensation expense of $2.1 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Structure Therapeutics Inc. reported the year ended December 31, 2023 results: net income For the year ended December 31, 2023, net loss totaled $89.6 million.

Period: the year ended December 31, 2023
Net income: For the year ended December 31, 2023, net loss totaled $89.6 million
Result: reported results

Exact text from the filing

For the year ended December 31, 2023, net loss totaled $89.6 million, with non-cash stock-based compensation expense of $8.2 million

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Structure Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-032121

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.